WebinarsHighlights from ESC Congress 2021
A comprehensive summary of the highlights from ESC Congress 2021 in ASCVD and lipidology. In the first specially compiled video, Professor Cannon and Professor Bhatt share their views on the late breaker results from REDUCE-IT and OMENI trials, along with the update ESC prevention guidelines. In the second video, Professor Cannon and Professor Nicholls discuss late-breaking results from the HUGYENs trial on evolcoumab, as well as the ESC prevention guidelines and the impact of the NHS approval of Inclisiran in improving patient care.
A comprehensive summary of the highlights from ESC Congress 2021 in ASCVD and lipidology. In the first specially compiled video, Professor Cannon and Professor Bhatt share their views on the late breaker results from REDUCE-IT and OMENI trials, along with the update ESC prevention guidelines. In the second video, Professor Cannon and Professor Nicholls discuss late-breaking results from the HUGYENs trial on evolcoumab, as well as the ESC prevention guidelines and the impact of the NHS approval of Inclisiran in improving patient care.